| Prev Close | 1.02 |
| Day Low/High | 0.91 / 1.14 |
| 52 Wk Low/High | 0.27 / 1.51 |
Adamis Pharmaceuticals Corporation (ADMP)
0.95
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 73.92B |
| Market Cap | 75.40M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Biotech Stocks Getting Their Due Respect
Here are two I think will bounce back before the end of the year.
2 Small Biotechs I Like in the Second Half
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
Why Is Flexion Falling, and Other Questions
The first part of Flexion's decline can be attributed to some profit taking.
2 Biotechs That Could Flex Their Muscles
Flexion Therapeutics and Adamis Pharmaceuticals are names to like at current levels.
These 3 Small Biotechs Have a Healthy Shot
Several firms hiked price targets on Portola into the $70s this week.
Give These 3 Small Biotechs a Shot
Several firms hiked price targets on Portola into the $70s this week.
Cruising Through the Grocery and Biotech Aisles
Looks like the grocery sector is going to be a theme for this Friday. In the story of the day, and maybe of the week, Amazon has announced it will buy organic food pioneer Whole Foods for $42 a share in an all-cash transaction. Walmart is down 5% i...
Stepping Up to the Plate, Your Pinch Hitter, Bret Jensen!
As always, I am happy to stand in today for Doug Kass here at the Daily Diary. We already are at the midway point of June and coming up on the end of the first half of the year as well. The markets have provided solid returns to this point. although...
Biotech Needs a Shot in the Arm
But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.
Biotech Needs a Shot in the Arm
But there is hope, as the FDA has approved almost as many new compounds in 2017 as in all of 2016.
Mylan Still Isn't Cheap
The EpiPen controversy makes this stock a shot in the dark.
Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians
Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.
